Clot Protection Benefits Evaluated for New Blood Gas Testing System
|
By LabMedica International staff writers Posted on 12 Sep 2012 |

Image: The Roche cobas b 123 POC blood gas testing system (Photo courtesy of Roche Diagnostics).
The clot protection capabilities of a new blood gas testing system have been highlighted in an evaluation undertaken at a hospital intensive care unit.
Blood sample clotting is a main concern in point-of-care (POC) testing systems (particularly in neonates for whom blood gases are the most common test performed) and can lead to delayed results and treatment, inconvenient analyzer downtime, and increased work and stress for hospital staff. At the intensive care unit of Stepping Hill Hospital of Stockport NHS Foundation Trust (Stockport, UK), 175 patient samples, including about 30 considered “high risk” for clotting, were analyzed in an evaluation of the new “Roche cobas b 123 POC” system from Roche Diagnostics (Basel, Switzerland). The tests were performed by nursing staff; quality control testing was performed automatically by AutoQC twice daily.
“We never had a problem with clots throughout the entire evaluation, despite using a wide variety of samples of varying condition and age,” said Samantha Ekin, Point of Care Coordinator (PCC) at the Trust. “This will be vital in a delivery suite setting where the quality of samples can be lower. The small size of the analyzer is great as it can be housed more easily, and it is portable.”
The cobas b 123 is specifically designed to eliminate risk of clot blockages. A new clot clearance feature prevents movement of clots from the syringe or capillary into the analyzer. This is achieved using a dual-action preanalytical barrier, with bottlenecks in the sample port needle and the cooximetry measuring chamber, so that clots are simply rinsed away with the sample by the automated default washing routine. Built-in optical sensors detect whether the lack of fluid path flow is due to a clot, in which case a series of automated expulsion steps remove the clot before continuing analysis uninterrupted.
To date, in both internal and external ongoing evaluations, no downtime owing to clots has been reported for the Roche cobas b 123 POC. The system is very easy to use and requires very little maintenance. “The whole process of analyzing a patient sample was very easy for the operator,” PPC Ekin continues; “This is very important because if the nurses like the analyzer they will have confidence to use it and confidence in the results. The low maintenance is also extremely important, especially for ‘out of hours’ work, as it enables the operators to perform any maintenance that might be required.” She adds that since training is very simple and requires less time, the procedure would be more accessible to additional staff.
Related Links:
Roche Diagnostics
Stockport NHS Foundation Trust
Blood sample clotting is a main concern in point-of-care (POC) testing systems (particularly in neonates for whom blood gases are the most common test performed) and can lead to delayed results and treatment, inconvenient analyzer downtime, and increased work and stress for hospital staff. At the intensive care unit of Stepping Hill Hospital of Stockport NHS Foundation Trust (Stockport, UK), 175 patient samples, including about 30 considered “high risk” for clotting, were analyzed in an evaluation of the new “Roche cobas b 123 POC” system from Roche Diagnostics (Basel, Switzerland). The tests were performed by nursing staff; quality control testing was performed automatically by AutoQC twice daily.
“We never had a problem with clots throughout the entire evaluation, despite using a wide variety of samples of varying condition and age,” said Samantha Ekin, Point of Care Coordinator (PCC) at the Trust. “This will be vital in a delivery suite setting where the quality of samples can be lower. The small size of the analyzer is great as it can be housed more easily, and it is portable.”
The cobas b 123 is specifically designed to eliminate risk of clot blockages. A new clot clearance feature prevents movement of clots from the syringe or capillary into the analyzer. This is achieved using a dual-action preanalytical barrier, with bottlenecks in the sample port needle and the cooximetry measuring chamber, so that clots are simply rinsed away with the sample by the automated default washing routine. Built-in optical sensors detect whether the lack of fluid path flow is due to a clot, in which case a series of automated expulsion steps remove the clot before continuing analysis uninterrupted.
To date, in both internal and external ongoing evaluations, no downtime owing to clots has been reported for the Roche cobas b 123 POC. The system is very easy to use and requires very little maintenance. “The whole process of analyzing a patient sample was very easy for the operator,” PPC Ekin continues; “This is very important because if the nurses like the analyzer they will have confidence to use it and confidence in the results. The low maintenance is also extremely important, especially for ‘out of hours’ work, as it enables the operators to perform any maintenance that might be required.” She adds that since training is very simple and requires less time, the procedure would be more accessible to additional staff.
Related Links:
Roche Diagnostics
Stockport NHS Foundation Trust
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








